Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to evaluate type 1 collagen deposition in the lungs following once-daily treatment with PLN-74809 for 12-weeks. This study is occurring at Massachusetts General Hospital.

Inclusion Criteria:Participants, aged 40 years or olderDiagnosis of IPF, within 8 years prior to ScreeningFVC % predicted ≥45%; historical FVC for entry in the study is permitted if within 1 month of screeningDiffusing capacity for carbon monoxide DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted if within 1 month of ScreeningParticipants currently receiving treatment for IPF with nintedanib or pirfenidone are permitted, if on a stable dose for at least 3 monthsExclusion Criteria:Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDAForced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio <0.7 at ScreeningClinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progressionKnown acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of ScreeningSmoking of any kind within 3 months of Screening